Elevated plasma phenylalanine associated with obesity, type 2 diabetes, and cancer risk.
High plasma phenylalanine linked to obesity, diabetes, and cancer risk
This systematic review examines epidemiological and mechanistic evidence regarding elevated plasma phenylalanine in metabolic disorders. The…
High blood phenylalanine is linked to obesity, type 2 diabetes, and cancer risk by blocking insulin signals and damaging mitochondria.
Systemic glucocorticoid exposure in children linked to reversible myocardial hypertrophy, subclinical cardiac changes
Review finds reversible heart changes in children taking certain steroid medications
A narrative review of pediatric systemic glucocorticoid exposure found the most consistent structural signal is time-locked, reversible myoc…
Certain steroid medicines used for childhood illnesses can temporarily thicken the heart muscle in very young babies, but this change appear…
Finerenone linked to improved KDIGO risk categories in T2D and CKD patients
Does finerenone help kidney risk categories improve in diabetes patients compared to placebo?
A post hoc subanalysis of an RCT in patients with type 2 diabetes and chronic kidney disease found finerenone therapy was associated with a …
Patients with diabetes and kidney disease taking finerenone were much more likely to see their kidney risk category improve and less likely …
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk and Improve Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart in certain adults.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug is approved to lower blood sugar and cut the risk of heart failure hospitalization in adults with type 2 diabetes and he…
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes pill that also helps protect the heart from failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill approved by the FDA also lowers the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Type 2 Diabetes and Heart Failure Risk Reduction
FDA approves a new diabetes pill that also helps protect the heart.
The FDA has approved dapagliflozin tablets for two indications: to improve glycemic control in adults with type 2 diabetes mellitus, and to …
A new daily diabetes pill now approved by the FDA helps lower blood sugar and reduces the risk of heart failure hospitalization for adults w…
FDA Approves Dapagliflozin for Reducing Heart Failure Hospitalization Risk and Improving Glycemic Control in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart.
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and estab…
A new diabetes drug now helps lower blood sugar while also reducing the risk of heart failure hospitalization for adults with heart disease …
FDA Approves Dapagliflozin Tablets (dapagliflozin) for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps lower the risk of heart failure.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and establ…
A new diabetes pill now helps lower blood sugar and reduces the risk of hospitalization for heart failure in adults with type 2 diabetes.
FDA Approves Dapagliflozin for Heart Failure Risk Reduction and Glycemic Control in Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart from failure.
The FDA has approved dapagliflozin to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established ca…
FDA approves a diabetes pill that lowers blood sugar and reduces heart failure hospitalization for adults with type 2 diabetes and heart ris…
FDA Approves Dapagliflozin Tablets (dapagliflozin) to Reduce Heart Failure Hospitalization Risk in Adults with Type 2 Diabetes
FDA approves a diabetes drug that also helps protect the heart.
The FDA has approved dapagliflozin tablets to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus a…
A new diabetes drug now protects the heart by lowering hospitalization risks for adults with type 2 diabetes and existing heart disease.
Produce Prescription Program Shows No Benefit for Cardiometabolic Outcomes in Food-Insecure Diabetes Patients
Produce prescription program did not improve health outcomes for patients with diabetes facing food insecurity
A randomized clinical trial of 2,155 patients with diabetes at risk for food insecurity found that a 12-month produce prescription program p…
A produce prescription program failed to improve health outcomes for patients with diabetes facing food insecurity in a major study.
BP variability and pulse pressure associated with cognitive decline in type 2 diabetes patients
Blood pressure swings linked to thinking problems in people with type 2 diabetes
A secondary analysis of 9,586 patients with type 2 diabetes from the ADVANCE trial found that higher blood pressure variability and baseline…
For people with type 2 diabetes, big swings in blood pressure are linked to a higher risk of memory and thinking problems down the road.